Jasco Pharmaceuticals, LLC is a privately held, pre-clinical stage drug discovery company focused on the discovery and development of small molecule oncology therapeutics. Jasco was founded with a core expertise in high speed medicinal chemistry providing a launching point for a chemical genomics approach to the discovery of selective protein kinase inhibitors. The company’s vision is to rapidly and effectively develop pre-clinical oncology candidates through IND submission and then guide them through the clinical development process by means of strategic partnerships. Website.
SIRO Clinpharm, winner of Frost & Sullivan ‘Clinical Research Organization of the year’ India Healthcare Award 2012 & 2011, is a drug development solutions provider to the global healthcare industry. Our subject expertise gives us an edge in clinical trial management, clinical data management, medical writing, biostatistics and statistical programming, pharmacovigilance and clinical trial supplies management. We offer flexible business models across service verticals based on client needs. Website.
SynDevRx is developing new and effective treatments for metabolic-related diseases including pre-diabetes, diabetes, obesity, dyslipidemia and fatty liver disease as well as treatments for cancer. Website.
TCG Lifesciences Limited (formerly Chembiotek) is a leading contract research organization in early drug discovery and development. We are a part of ‘The Chatterjee Group’ (TCG), a global investment conglomerate headquartered in New York with strategic investments of over USD 1 Billion.
Spread over 250,000 sq. ft. of space our services span from specific solutions to integrated discovery projects across multiple therapeutic areas with focus on Central Nervous System (CNS), Inflammation & Pain, Metabolic Disorders and Infectious Diseases. Website.
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Website.
We have assembled an experienced team of clinical research professionals focusing on quality research data while recognizing that speed, responsiveness and accountability are also core needs of our clients. Website.
1) JobWatch: Massachusetts Reveals 2020 Vision - GEN, April 11, 2014
Massachusetts’ biopharma cluster is among the world’s biggest and best with more than 56,000 jobs, universities like Harvard and MIT, and a rich heritage stretching from Genzyme’s founding in 1981. Link
2) Lilly and T1D Exchange Announce Research Collaboration to Inform Development of New Initiatives to Advance Diabetes Care – Wall Street Journal, April 9, 2014
T1D Exchange and Eli Lilly and Company announced today they have entered into a research collaboration that will enable both organizations to gain deeper, real-world insight about the experience of people with type 1 diabetes, to identify new ways to improve care and advance outcomes. Link
3) Genzyme to resubmit application for multiple sclerosis drug, Lemtrada, to FDA - Boston Business Journal, April 7, 2014
Genzyme announced today it plans to submit its once-a-year drug, which is approved outside the U.S. for multiple sclerosis, to U.S. regulators after it was rejected in December. Link
4) Biogen’s hemophilia hopeful scores a PhIII win as FDA awaits - Fierce Biotech, April 10, 2014
Biogen Idec’s ($BIIB) long-acting hemophilia A drug performed well in a late-stage study on children, the biotech said, giving it another Phase III victory as it races with rivals Bayer and Novo Nordisk ($NVO) to launch a more convenient treatment for the bleeding disorder. Link
5) UPDATED: Alkermes hits PhIII goal line with ‘blockbuster’ long-acting schizophrenia drug – Fierce Biotech, April 8, 2014
Alkermes has crossed the finish line in a Phase III schizophrenia study of a long-acting version of Abilify, picking up the statistically significant results needed to back a new drug application later in the year. The company’s shares ($ALKS) shot up 10% in early trading Tuesday. Link
Nearly 400 biotechnology industry leaders gathered last week at the Royal Sonesta Hotel in Cambridge, right in the heart of the state’s biotech cluster, to participate in MassBio’s 2014 Annual Meeting.
The meeting took place over two days, and included discussions on relationships between biotech, pharma, investors, & academia, value cost effectiveness, funding early stage companies, clinical trial trends, and more. At the Annual Meeting, we also we released our quinquennial industry strategic report, Impact 2020.
The Annual Meeting kicked off with welcome remarks by Bob Coughlin, President & CEO of MassBio, as well as an overview of the meeting agenda.
In an opening keynote, Brad Margus, CEO of Genome Bridge shared his personal journey of working to advance research for ataxia-telangiectasia, or A-T, an extremely rare disease.
At the awards luncheon on Thursday afternoon, Assabet Valley Regional Technical High School received the Joshua Boger Innovative School of the Year Award from MassBioEd, presented by Takeda. We heard from Assabet teacher Monica Hayes, and student Alexander McMahon who shared his passion for pursuing a career in biotechnology.
1) Coverage of the MassBio Annual Meeting:
- Biotech sector fears financial squeeze – Boston Globe 4/3/14
- Biogen Idec chief warns against funding cuts - Boston Globe 4/3/14
- MassBio panel tackles drug industry’s bad reputation – Boston Business Journal 4/3/14
- Marlborough: Assabet receives biotech recognition – Metro West Daily News 4/3/14
- Assabet Valley named MassBioEd Innovative School of the Year – Marlborough Wicked Local 4/3/14
- New Report Outlines Future of Biotech in Massachusetts – BIOtechNOW 4/3/14
- MassBio Issues Impact 2020 Report Outlining the Future of Biotech – BroadWayWorld.com 4/3/14
- Report: Spending cuts challenge biotech research, startups – Worcester Business Journal Online 4/3/14
- FDA head says agency’s work has helped shorten time needed for drug approval -Boston Business Journal 4/4/14
- The true costs of developing life-saving, innovative new drugs – Boston Business Journal 4/4/14
- FOX follow up: FDA commissioner responds to mothers’ plea - MyFOXboston.com 4/4/14
- FDA chief urges ‘new era of partnership’ - Boston Globe 4/5/14
- FDA chief touts faster drug approvals in Hub visit – Boston Herald 4/5/14
2) Biogen’s stock slide is halted by hemophilia drug approval in the U.S. – Boston Business Journal 3/31/14
The U.S. approval of Biogen Idec’s first hemophelia drug has helped reverse — for now — one of the fastest stock slides the company has seen in recent years, while analyst optimism has not wavered in the face of the recent biotech selloff. Link
3) Stallergenes beats Merck to market as FDA OKs its allergy pill - Fierce Biotech 4/2/14
France’s Stallergenes won FDA approval to market the U.S.’s first oral immunotherapy for grass allergies, giving it a head start on rival Merck ($MRK), which expects to launch a similar product this year. Link
4) Forma Therapeutics makes deal with Celgene potentially worth $600M - Boston Business Journal 4/1/14
Watertown biotech firm Forma Therapeutics has announced a collaboration with drug giant Celgene Corp. potentially worth $600 million over the course of the next several years. Link
5) FDA panel votes in favor of approval for Cubist’s new MRSA drug – Boston Business Journal 3/31/14
An advisory committee to the U.S. Food and Drug Administration voted unanimously in favor of approval for the newest antibiotic by Cubist Pharmaceuticals, according to a spokeswoman for the company. Link
Guest Post by Maude Tessier, Assistant Director, Business Development and Strategic Initiatives, TIDO of Boston Children’s Hospital
According to Ernst and Young, Europe represents about 30% of the total pharmaceutical sales worldwide, second only to North America which represents 40%. We’ve all read news pieces about how UK’s N.I.C.E. is sometimes not very “nice” to biotech and pharma companies, but how well do you know this territory’s current, as well as future, challenges and opportunities? I believe that the US has a lot to learn about what’s going on in Europe and these trends happening over the ocean affect us here in Boston. As Asian and Emerging markets rise, we seem to hear less about Europe. However, with a strong academic base, highly skilled workforce, and a number of government incentives, Europe continues to be an important territory in any biopharmaceutical company strategy as a market for products and as a venue for collaboration at all stages of drug development.
The second part of the “Around the World in 120 Days” Forum series on April 10th will introduce key concepts of performing business in Europe and will provide an opportunity to reflect on how this market is evolving. We have a stellar lineup of international presenters and panelists (folks are flying in from the U.K. and from Denmark!), led by moderator Mark Leuchtenberger, CEO of Acusphere and member of MassBio’s Board of Directors. We will discuss topics such as:
- What is the intrinsic value of the EU commercial opportunity? How has this relative value increased, decreased, or remained the same over the last ten years?
- What are the greatest potential opportunities and pitfalls that companies face when attempting to extend their operations into the EU?
- What are the factors that influence corporate development decisions to invest in EU at each stage?
- What are the advantages and disadvantages of partnering/collaborating with a European company?
Please join us as knowledgeable executives tackle these subjects and, importantly, share memorable stories from their own experiences. You’ll also get the chance to interact with several foreign delegations that will be in attendance. Kick start your European strategy with MassBio!
About the author: Maude Tessier is Assistant Director, Business Development and Strategic Initiatives, TIDO of Boston Children’s Hospital. Maude joined TIDO of Boston Children’s Hospital in 2008. Maude’s role is to initiate, develop and realize partnerships and alliances between Boston Children’s and industry partners that create value at all stages of development, and including pre-clinical and clinical investigation.